Compare VENUS REMEDIES with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SANOFI INDIA VENUS REMEDIES/
SANOFI INDIA
 
P/E (TTM) x -1.3 36.0 - View Chart
P/BV x 0.1 6.3 1.5% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 VENUS REMEDIES   SANOFI INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
SANOFI INDIA
Dec-18
VENUS REMEDIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1266,840 1.8%   
Low Rs614,630 1.3%   
Sales per share (Unadj.) Rs301.81,203.1 25.1%  
Earnings per share (Unadj.) Rs-24.9165.3 -15.0%  
Cash flow per share (Unadj.) Rs2.5209.9 1.2%  
Dividends per share (Unadj.) Rs084.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs293.3963.6 30.4%  
Shares outstanding (eoy) m12.3423.03 53.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.8 6.5%   
Avg P/E ratio x-3.834.7 -10.8%  
P/CF ratio (eoy) x36.727.3 134.5%  
Price / Book Value ratio x0.36.0 5.4%  
Dividend payout %050.8 0.0%   
Avg Mkt Cap Rs m1,154132,078 0.9%   
No. of employees `0000.93.3 28.0%   
Total wages/salary Rs m3934,068 9.7%   
Avg. sales/employee Rs Th4,026.18,393.8 48.0%   
Avg. wages/employee Rs Th425.01,232.4 34.5%   
Avg. net profit/employee Rs Th-331.81,153.0 -28.8%   
INCOME DATA
Net Sales Rs m3,72427,708 13.4%  
Other income Rs m23897 2.5%   
Total revenues Rs m3,74728,605 13.1%   
Gross profit Rs m3956,235 6.3%  
Depreciation Rs m3381,027 32.9%   
Interest Rs m3547 5,061.4%   
Profit before tax Rs m-2756,098 -4.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m322,292 1.4%   
Profit after tax Rs m-3073,806 -8.1%  
Gross profit margin %10.622.5 47.1%  
Effective tax rate %-11.537.6 -30.5%   
Net profit margin %-8.213.7 -60.0%  
BALANCE SHEET DATA
Current assets Rs m2,63815,922 16.6%   
Current liabilities Rs m2,3056,235 37.0%   
Net working cap to sales %8.935.0 25.6%  
Current ratio x1.12.6 44.8%  
Inventory Days Days13564 212.8%  
Debtors Days Days4621 222.0%  
Net fixed assets Rs m4,8717,539 64.6%   
Share capital Rs m123230 53.7%   
"Free" reserves Rs m3,49621,962 15.9%   
Net worth Rs m3,61922,192 16.3%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50929,839 25.2%  
Interest coverage x0.2872.1 0.0%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.9 53.4%   
Return on assets %0.612.8 4.9%  
Return on equity %-8.517.2 -49.4%  
Return on capital %1.627.5 5.8%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m07,587 0.0%   
Fx outflow Rs m5177,145 7.2%   
Net fx Rs m-517442 -116.9%   
CASH FLOW
From Operations Rs m5143,739 13.8%  
From Investments Rs m-123-731 16.8%  
From Financial Activity Rs m-387-1,972 19.6%  
Net Cashflow Rs m41,036 0.4%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.2 14.4 1.3%  
FIIs % 0.6 14.6 4.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.5 632.4%  
Shareholders   20,121 15,184 132.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 17, 2019 03:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - SUVEN LIFESCIENCES COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS